Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs
Increasingly Crowded Field
The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.
You may also be interested in...
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
In a vote of confidence, investors predict Shanghai IPOs to rise in 2022, while sluggish share performances in Hong Kong have made a public listing there more “a liquidity rather than an exit event.”
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.